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 Abstract 
Background: Alkaptonuria (AKU) is caused by homogentisate 1,2-dioxygenase deficiency 
that leads to homogentisic acid (HGA) accumulation, ochronosis and severe 
osteoarthropathy. Recently, nitisinone treatment, which blocks HGA formation, has been 
effective in AKU patients. However, a consequence of nitisinone is elevated tyrosine that 
can cause keratopathy. The effect of tyrosine and phenylalanine dietary restriction was 
investigated in nitisinone-treated AKU mice, and in an observational study of dietary 
intervention in AKU patients. 
Methods: Nitisinone-treated AKU mice were fed tyrosine/phenylalanine-free and 
phenylalanine-free diets with phenylalanine supplementation in drinking water. Tyrosine 
metabolites were measured pre-nitisinone, post-nitisinone, and after dietary restriction. 
Subsequently an observational study was undertaken in 10 patients attending the National 
Alkaptonuria Centre (NAC), with tyrosine >700µmol/L who had been advised to restrict 
dietary protein intake and where necessary, to use tyrosine/phenylalanine-free amino acid 
supplements. 
Results: Elevated tyrosine (813µmol/L) was significantly reduced in nitisinone-treated AKU 
mice fed a tyrosine/phenylalanine-free diet in a dose responsive manner. At 3 days of 
restriction, tyrosine was 389.3µmol/L, 274.8µmol/L and 144.3µmol/L with decreasing 
phenylalanine doses. In contrast, tyrosine was not effectively reduced in mice by a 
phenylalanine-free diet; at 3 days tyrosine was 757.3µmol/L, 530.2µmol/L and 656.2µmol/L, 
with no dose response to phenylalanine supplementation. In NAC patients, tyrosine was 
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significantly reduced (p=0.002) when restricting dietary protein alone, and when combined 
with tyrosine/phenylalanine-free amino acid supplementation; 4 out of 10 patients achieved 
tyrosine <700µmol/L.   
Conclusion: Tyrosine/phenylalanine dietary restriction significantly reduced nitisinone-
induced tyrosinaemia in mice, with phenylalanine restriction alone proving ineffective. 
Similarly, protein restriction significantly reduced circulating tyrosine in AKU patients.  
Take home message: Reducing dietary intake of tyrosine/phenylalanine reduces nitisinone-
induced tyrosinaemia.  
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Introduction 
Alkaptonuria (AKU; OMIM #203500) is an autosomal recessive, multisystem disease caused 
by mutations in the homogentisate 1,2-dioxygenase (HGD) enzyme (EC 1.13.11.5; La Du et 
al. 1958). HGD deficiency leads to homogentisic acid (HGA) accumulation (figure 1A) in the 
blood and tissues. Over time, excess HGA forms a dark brown ochronotic pigment that 
deposits in connective tissues causing them to become stiff and  brittle (Gaines and Pai 
1987; Janocha et al. 1994; Helliwell et al. 2008; Taylor et al. 2011), leading to early-onset 
and severe osteoarthropathy.  
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Recently, a drug called nitisinone (2-(2-nitro-4-(trifluoromethyl)benzoyl) cyclohexane-1,3-
dione; NTBC) that blocks 4-hydroxyphenylpyruvic acid dioxygenase (HPPD; EC 1.13.11.27) 
which converts 4-hydroxyphenylpyruvic acid (HPPA) into HGA was shown to prevent 
ochronosis in AKU mice (Preston et al. 2014; Keenan et al. 2015), leading to a series of 
human clinical trials assessing nitisinone in AKU (Ranganath et al. 2014). The SONIA-1 trial 
concluded that nitisinone effectively reduces HGA to a level likely to prevent ochronosis 
(Ranganath et al. 2014). However, increased serum tyrosine was seen with nitisinone 
treatment (Ranganath et al. 2014). 
 
Elevated serum tyrosine (tyrosinaemia) causes eye and skin keratopathy in nitisinone-
treated hereditary tyrosinaemia type 1 (HT-1; OMIM #276700)(Masurel-Paulet et al. 2008),  
resembling the dermal and ocular symptoms seen in hereditary tyrosinaemia type II (OMIM 
#276600)(Macsai et al. 2001). Low-dose nitisinone (0.5mg daily) in an AKU patient has 
induced ocular irritation and photophobia that presented before corneal crystal deposition 
(White and Tchan 2018). More worryingly, a study reported mild corneal keratopathy  in an 
AKU patient on 2mg of nitisinone daily with no ocular symptoms or pain (Khedr et al. 2018). 
This is concerning as untreated keratopathy could be sight-threatening if not detected. 
 
Moreover, the association of tyrosinaemia with neural cognition is another important 
consideration, as tyrosine is a precursor to neurotransmitters such as dopamine, adrenaline 
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and noradrenaline. Metabolites of these neurotransmitters have previously been shown to 
significantly alter with nitisinone treatment in AKU patients (Davison et al. 2018a). Similarly, 
numerous reports and studies document impaired cognitive function in HT-1 patients that 
have been treated long-term with nitisinone and protein restriction (Masurel-Paulet et al. 
2008; Thimm et al. 2012; van Ginkel et al. 2016).  These neurodevelopmental effects 
however could be due to either nitisinone-induced tyrosinaemia or severe liver failure 
experienced before diagnosis and subsequent initiation of nitisinone treatment. With the 
cause of impaired cognition in HT-1 remaining to be elucidated, the off-licence use of 
nitisinone has been restricted to ≥16 years in AKU. 
 
A tyrosine-lowering strategy that can prevent keratopathy, such as protein/tyrosine 
restriction, is implemented in conjunction with nitisinone treatment in HT-1 (de Laet et al. 
2013; Mayorandan et al. 2014). However, poor adherence to protein supplements coupled 
with an inadequate low protein diet, can lead to essential amino acid and micronutrient 
deficiency (Acosta and Matalon 2010; van Spronsen et al. 2017). Although advised, no 
clinical study has investigated the effectiveness of dietary restriction at reducing nitisinone-
induced tyrosinaemia in AKU. 
 
Here, dietary restriction of tyrosine and phenylalanine was investigated in nitisinone-treated 
AKU mice to establish its effectiveness at reducing tyrosinaemia. Additional observational 
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data of dietary intervention in AKU patients attending the National Alkaptonuria Centre 
(NAC; Liverpool, UK), where patients receive 2mg nitisinone daily, is presented. At the NAC, 
serum tyrosine increases to a mean level of approximately 600-700µmol/L (Milan et al. 
2017; Davison et al. 2018b) with nitisinone, therefore patients are advised to restrict protein 
intake with guidance from a specialist dietician. We provide proof-of-concept that 
mechanisms reducing uptake of dietary tyrosine into the bloodstream would be effective.  
 
Methods 
Mice 
BALB/c Hgd-/- mice (Preston et al. 2014), referred to as AKU, were all housed and 
maintained within the University of Liverpool Biological Services Unit in specific pathogen 
free conditions in accordance with Home Office UK guidelines. Food and water were 
available ad libitum.  
 
Dietary Restriction Studies 
To investigate tyrosine and phenylalanine dietary restriction on nitisinone-induced 
tyrosinaemia and on other tyrosine pathway metabolites, AKU mice (n=6; 3 male, 3 female) 
were treated with nitisinone for 1 week on normal diet, then switched to either 
tyrosine/phenylalanine-free or phenylalanine only-free diets with phenylalanine 
supplemented into the drinking water to investigate dose response, whilst still on nitisinone. 
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Controls remained on normal diet. Blood samples were taken pre-nitisinone, 1 week post-
nitisinone and then during dietary restriction. 
 
Diets 
The normal control mouse diet (CRM(P), product code 801722, Special Diet Services (SDS), 
UK), contained 0.88% phenylalanine and 0.59% tyrosine. Restricted diets were synthetically 
made by SDS in pellet form. Synthetic raw materials were used to produce an amino acid 
defined diet which has an amino acid profile similar to the normal CRM(P) diet, with 
tyrosine and/or phenylalanine removed and balanced on maize starch.  
 
Nitisinone and phenylalanine provision in drinking water 
Nitisinone was added to the drinking water at 4mg/L (0.8mg/kg; based on 30g mouse 
drinking approximately 6ml/day) and was freely available. Phenylalanine was added to the 
drinking water at various doses, between 0-5mg/ml as indicated in the results.  
 
Calculating dietary restriction 
Daily food and water intake is approximately 5g and 6ml respectively, per 30g bodyweight 
for the BALB/cByJ strain (Bachmanov et al. 2002). A 30g mouse on the normal CRM(P) diet 
therefore consumes approximately 44mg/day phenylalanine and 29.5mg/day tyrosine. In 
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the tyrosine/phenylalanine-free diet study, drinking water was supplemented with 5mg/ml, 
2.5mg/ml and 1.25mg/ml phenylalanine, equating to approximately 68% phenylalanine/0% 
tyrosine, 34% phenylalanine/0% tyrosine and 17% phenylalanine/0% tyrosine, respectively. 
In the phenylalanine free diet study, drinking water was supplemented with 2.5mg/ml, 
0.625mg/ml and 0mg/ml phenylalanine, equating to approximately 34% 
phenylalanine/100% tyrosine, 8.5% phenylalanine/100% tyrosine and 0% 
phenylalanine/100% tyrosine, respectively.   
 
Blood Collection from mice 
Acidified plasma from venous tail bleeds was collected to analyse tyrosine pathway 
metabolites via HPLC tandem mass spectrometry (Hughes et al. 2015).  
 
National Alkaptonuria Centre (NAC) patients 
NAC patients receive off-licence treatment of 2mg nitisinone daily, dietary advice and have 
serum tyrosine monitored at yearly visits (Milan et al. 2017). The NAC aims to achieve 
tyrosine <500µmol/L. Tyrosine thresholds of 500-700µmol/L and 700-900µmol/L are used as 
guidleines for reducing dietary protein consumption to 0.9g and 0.8g protein/kg 
bodyweight/day respectively. Patients with tyrosine >700µmol/L are more closely 
monitored with additional blood sampling if required. Fasting blood samples were taken in 
the morning. Ten anonymised NAC patients with tyrosine >700µmol/L are reported here. All 
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patients received advice to reduce dietary protein intake to a recommended minimum level 
of 0.75g protein/kg bodyweight/day, to reduce circulating tyrosine whilst meeting minimum 
nutritional requirements. A TYR cooler® (Vitaflo, UK) protein substitute (free in 
tyrosine/phenylalanine) drink was used by 7/10 patients. TYR cooler dosage was determined 
by the dietician for each individual; protein removed from the diet, below the 
recommended minimum, was exchanged for the equivalent amount of protein in the cooler. 
These patients had been attending the NAC  for a mean of 36.5 months [range 29-48] at the 
initial tyrosine concentration, with a mean age of 56 years [range 29-71]. The gender of 
patients was 5 male, 5 female. 8 were white British, 1 was Indian and 1 was Pakistani. 
 
Statistical analysis  
Statistical analysis was performed using Stats Direct 3 statistical software (England, UK). 
Means are represented as mean±standard error on the mean (SEM). Statistical significance, 
using α=0.05; p<0.05 *, p<0.01 **, p<0.001 ***. Error bars represent SEM.  
 
Results 
Effect of nitisinone treatment on tyrosine pathway metabolites 
Tyrosine pathway metabolites were measured in the plasma of 24 AKU mice pre- and post-
nitisinone treatment (4mg/L in drinking water for 7 days) (figure 2B). HGA was significantly 
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decreased 8-fold from 255.1±43.2µmol/L to 32.9±3.2µmol/L whilst all other metabolites 
increased; all changes were significant (p<0.001, two-tailed paired t-test). Tyrosine 
increased 11-fold from 72.9±3.6µmol/L to 813.3±37.6µmol/L. Phenylalanine increased 1.5-
fold from 67.3±2.4µmol/L to 100.8±4.9µmol/L. HPPA increased 14.5-fold from 
10.5±0.4µmol/L to 151.8±12.9µmol/L. 4-hydroxyphenyllactic acid (HPLA) increased 19-fold 
from 2.0±0.2µmol/L to 38.6±3.0µmol/L. 
 
Tyrosine/phenylalanine dietary restriction 
Nitisinone-treated AKU mice were fed a tyrosine and phenylalanine-free diet, with 
phenylalanine supplemented into the drinking water (5-1.25mg/ml). The control group 
remained on a normal diet. Blood samples were taken according to the scheme in figure 2A. 
Three days after dietary restriction, tyrosine was reduced from 813.3±37.6µmol/L (all 
groups, n=24; figure 2B) in a dose responsive manner to 389.3±42.3µmol/L, 
274.8±6.3µmol/L, 144.3±13.0µmol/L in the 5mg, 2.5mg and 1.25mg restricted groups, 
respectively. After 14 days of restriction, these reductions were maintained. All comparisons 
to the control group at both 3 and 14 days were significant (p<0.001). 
 
After 3 days of dietary restriction, significant reductions in phenylalanine, HGA, HPPA and 
HPLA were present, however the dose response was not as clear in these metabolites 
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(figure 2B). After 14 days of dietary restriction, only HGA and HPLA showed significant 
reductions compared to the control group.  
 
A second tyrosine/phenylalanine dietary restriction study (data not shown) was carried out, 
with lower doses of phenylalanine supplementation in the water (0.625mg/ml, 
0.3125mg/ml and 0mg/ml). Further restriction of phenylalanine however did not result in 
lower plasma tyrosine concentrations than those shown in figure 2, at both 3 and 4 days of 
restriction. No significant weight changes were seen between any of the groups at 4 days of 
restriction. 
 
Phenylalanine only dietary restriction 
Nitisinone-treated AKU mice were fed a phenylalanine-free diet with normal tyrosine, with 
phenylalanine supplemented in drinking water (2.5-0mg/ml). The control group remained 
on a normal diet. Blood samples were taken according to the scheme in figure 3A. Plasma 
tyrosine was 63.5±2.7µmol/L pre-nitisinone and increased to 748.9±26.8µmol/L post-
nitisinone (n=24, all groups, figure 3B). After 3 days of phenylalanine restriction, tyrosine 
levels were 757.3±54.9µmol/L, 533.2±28.8µmol/L and 656.2±69.6µmol/L, with only the 
latter two groups, (0.625mg/ml and phenylalanine-free), being significantly different to 
control (p<0.001 and p=0.014, respectively). After 7 days of dietary restriction, none of the 
restricted groups had significantly lower tyrosine compared with the control group.  
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 Significant reductions in plasma phenylalanine were seen at both 3 days (all groups p<0.001 
compared with control) and after 7 days (0.625mg/ml and phenylalanine-free, both p<0.001 
compared with control; 2.5mg/ml not significantly different, p=0.065) of phenylalanine 
dietary restriction. HPLA demonstrated significant differences after 3 days in the 
0.625mg/ml and phenylalanine-free groups however these significant differences were not 
maintained after 7 days. HGA showed significant differences after 7 days of dietary 
restriction in all the restricted groups however these differences were not seen after 3 days. 
HPPA was not significantly reduced in the restricted groups compared with control, at 
neither 3 nor 7 days of dietary restriction. 
 
Body weight 
The extent of tyrosine/phenylalanine dietary restriction (%) in these studies was based upon 
daily food and water intake values for mice weighing 30g. At day 7 when dietary restriction 
was implemented, the mean body weight of all mice (n=24) was 29.8g (23.5–35.7g) and 
30.0g (23.7–37.1g) in the tyrosine/phenylalanine-free and phenylalanine only-free diet 
studies respectively.  
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Individual body weight was monitored over the duration of dietary restriction. At 14 days of 
restriction in the tyrosine/phenylalanine-free diet study, the restricted groups showed no 
significant change in body weight (figure 2C) compared to the control group (p=0.841).  
 
Figure 3C shows the changes in body weight after 7 days of restriction in the phenylalanine 
only diet study. One-way ANOVA demonstrated a significant difference in weight change 
between the groups (p=0.014), with differences found between the 2.5mg/ml group 
compared with the 0.625mg/ml (p=0.23) and phenylalanine-free (p=0.021) groups (post-hoc 
Tukey test). None of the restricted groups however showed weight changes significantly 
different to the control group. 
 
NAC dietary intervention in AKU patients 
Average estimated protein intake from 7-day food diaries in all AKU patients attending the 
NAC was 1.1g protein/kg bodyweight/day at baseline visit 1 (unpublished data) before any 
intervention, which is comparable with the general population (NDNS2016). With nitisinone, 
dietary protein intake is restricted to a recommended minimum level of 0.75g protein/kg 
bodyweight/day (SACN/COMA2008/2017), with additional metabolic requirements 
provided by prescribed tyrosine/phenylalanine-free amino acid supplements in some 
patients.  
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 Overall, significant reductions in serum tyrosine (figure 4) were seen in the 10 NAC patients 
observed (p=0.002; two-tailed Wilcoxon’s signed rank test), with 4 patients reducing serum 
tyrosine <700µmol/L. Three patients (figure 4, dashed lines) reduced serum tyrosine 
(mean[range]) by 22[18-30]% by advised protein restriction alone; the other 7 patients 
required a combination of reduced protein intake with tyrosine/phenylalanine-free 
supplements to achieve a 33[8-62]% reduction. The initial tyrosine value for patients using 
amino acid supplements was with dietary restriction alone, with subsequent values using a 
combination of reduced protein intake and amino acid supplementation. Across all 10 
patients and all sample time points, phenylalanine (mean[range]) was 57[38-108]µmol/L.  
 
Discussion 
The treatment of AKU with the HGA-lowering drug nitisinone has proven to be effective at 
reducing HGA (Ranganath et al. 2018a). However, data from clinical trial (Ranganath et al. 
2014) and off-label prescription use at the NAC (Milan et al. 2017) clearly demonstrate 
concomitant elevation of tyrosine. Tyrosinaemia can cause eye and skin keratopathy in a 
minority of patients requiring a lower dose or cessation of nitisinone, or a strict low protein 
diet, to resolve symptoms. Low-dose nitisinone, ranging from 0.5-2mg daily, has caused eye 
complications in 5 reported AKU patients to date (Introne et al. 2011; Stewart et al. 2014; 
Khedr et al. 2018; White and Tchan 2018). Attempting to restrict dietary tyrosine and 
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phenylalanine consumption, whilst taking nitisinone to keep HGA low, is the most logical 
approach to combat tyrosinaemia. A protein restricted diet however proves very difficult to 
maintain and often causes keratopathy to return when not adhered to (Khedr et al. 2018). 
Therefore, finding an alternative strategy to reduce dietary uptake of tyrosine and/or 
phenylalanine would allow nitisinone-treated AKU patients to consume a normal protein 
diet. Before such strategies are investigated, the findings of this paper has showed that 
reducing dietary tyrosine/phenylalanine is effective at reducing tyrosine in AKU mice, with 
similar observational evidence that lowering tyrosine via dietary intervention in patients is 
achievable, therefore establishing a proof of principle for targeting dietary 
tyrosine/phenylalanine in patients who are on nitisinone. 
 
Tyrosine threshold recommendations with nitisinone treatment, which are often arbitrary, 
vary in the literature. In HT-1 children <12 years, the recommended tyrosine level is 200-
400µmol/L, with concentrations after this age allowed to rise, with eye complications 
experienced >800µmol/L (de Laet et al. 2013). Another HT-1 review of 22 centres treating 
patients aged 0-24 years found maximum acceptable tyrosine levels to be 200-800µmol/L, 
with 400µmol/L determined to be a safe and feasible target (Mayorandan et al. 2014). A 
report of an adult AKU patient who experienced eye keratopathy whilst receiving low-dose 
nitisinone (0.5-1.5mg daily) suggests a target tyrosine of <600µmol/L (White and Tchan 
2018), whilst a more recent NAC publication suggests <500µmol/L is acceptable (Ranganath 
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et al. 2018b). NAC tyrosine thresholds are designed to fit a dietetic care plan, that aims to 
reduce serum tyrosine in order to prevent symptomatic keratopathy, with systematic 
removal of dietary protein, whilst taking into account compliance difficulites experienced in 
patients.   
 
In this study, the mouse tyrosine/phenylalanine-free diet clearly showed a dose-responsive 
reduction in plasma tyrosine, with all groups reaching <400µmol/L. The least restricted 
group (5mg/ml) reduced tyrosine to 389µmol/L at 3 days, achieved with approximately 68% 
phenylalanine/no tyrosine. We also showed evidence that human patients on nitisinone can 
reduce serum tyrosine with dietary intervention. Tyrosine was significantly lowered either 
by a low protein diet alone or in combination with prescribed tyrosine/phenylalanine-free 
amino acid supplementation. Although 4/10 patients achieved tyrosine <700µmol/L, 
tyrosine was greatly reduced in some patients, notably from 1084µmol/L to 762µmol/L, and 
from 1217µmol/L to 859µmol/L. Of the 4 patients that reduced tyrosine below 700µmol/L, 
only 1 patient achieved this with dietary advice alone; the other 3 patients used amino acid 
supplementation. Prior to nitisinone, most adult AKU patients will have consumed a normal 
protein diet throughout their life, therefore adaption to dietary changes can be difficult, 
especially in the absence of tyrosine-related keratopathy where no benefit is perceived. 
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The NAC patient data was not collected as a controlled trial, but as an observational study 
where patients are only advised to restrict their protein intake, therefore strict monitoring 
of compliance and protein intake was not carried out. After specialist advice, patients were 
responsible for restricting dietary protein in their daily lives, with guidance from the 
dietician if needed. Progress with dietary compliance is a long-term iterative process, since 
achieving long-term, sustained behaviour change in adults is a recognised national dilemma. 
Compliance is the most likely reason that only 1/10 NAC patients achieved <500µmol/L 
tyrosine and is why mice were used for the restriction experiments reported here. The diets 
of mice are easy to control, in addition to eliminating other confounding factors such as 
lifestyle, exercise, mobility and disease severity differences. The mouse data provides 
evidence that dietary restriction of tyrosine/phenylalanine can effectively reduce nitisinone-
induced tyrosinaemia, providing the rationale to carry out a controlled trial in human AKU 
patients, where lower tyrosine levels than those presented here would be expected.  
 
In mice, the dose response observed due to phenylalanine supplementation, in the absence 
of tyrosine (figure 2), suggests that tyrosine derived from phenylalanine is important to 
target. However, phenylalanine only restriction was ineffective at lowering nitisinone-
induced tyrosinaemia, even with complete phenylalanine restriction (figure 3). This is an 
important consideration as emerging experimental and dietary phenylalanine-lowering 
strategies for the metabolic disease phenylketonuria (OMIM #261600) may have been 
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beneficial for nitisinone-induced tyrosinaemia if phenylalanine restriction alone had proven 
effective. Such strategies include enzymatic phenylalanine degradation by exogenous 
phenylalanine ammonia lyase enzyme, diets supplemented with naturally occurring 
glycomacropeptide (GMP) protein that is naturally low in phenylalanine instead of synthetic 
amino acid foods, and genetically modified probiotics that target phenylalanine-degradation 
in the intestine (Al Hafid and Christodoulou 2015; Bell et al. 2017).  
 
Due to phenylalanine being an essential amino acid, its restriction alone could lead to 
inadequate protein turnover, with the balance of catabolism/anabolism disrupted, causing a 
loss of lean mass (Yannicelli 2015). Although not significantly different to the control group 
in the phenylalanine only restriction study, there was a significant body weight reduction in 
the phenylalanine-free and 0.625mg/ml groups compared to the 2.5mg/ml group (figure 3) 
at 7 days. This weight loss was seen in the presence of tyrosine, suggesting that 
phenylalanine restriction could lead to catabolism, therefore targeting tyrosine would be 
more desirable. At 14 days of restriction, no significant weight changes were seen in figure 2 
in which tyrosine was absent and phenylalanine was partially present.  
 
It is essential to balance lowering protein intake in order to lower tyrosine, with maintaining 
a healthy weight and muscle mass, since catabolism itself provides residual tyrosine. During 
routine NAC visits, anthropometric data such as such as grip, mid upper arm circumference 
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and bioimpedance data such as lean mass and fat mass, is collected to provide sequential 
evidence of body composition trends to minimise risk of catabolism. These parameters were 
not investigated in the AKU patients presented in figure 4, as less than half of the tyrosine 
concentrations were measured at a routine (yearly) NAC visit, where such anthropometric 
data is collected. These parameters are worthy of investigation in both mice and humans in 
the future.  
 
In addition to decreased tyrosine, other metabolic improvements were observed with 
dietary restriction in mice. HGA, which is lowered with nitisinone treatment, was then 
significantly lowered in the restricted groups compared to the control in the 
tyrosine/phenylalanine-free study. Both HPPA and HPLA in mice, which were elevated with 
nitisinone as recently shown in human AKU patients (Milan et al. 2019), were significantly 
reduced compared to the control with restriction. Although the effect of elevated HPPA and 
HPLA is unknown, reducing them back towards normal physiological levels would be 
desirable. Phenylalanine in mice was significantly reduced after 3 days in the 
tyrosine/phenylalanine restriction study, but this was not maintained to 14 days. In human 
NAC patients, phenylalanine levels were within the normal reference range. 
 
Nitisinone is a lifelong treatment for AKU and is associated with hypertyrosinaemia. 
Removal of tyrosine/phenylalanine, but not phenylalanine alone, from the diet of mice is 
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effective at reducing nitisinone-induced tyrosinaemia. Protein restriction coupled with 
tyrosine/phenylalanine-free amino acid supplementation was able to reduce tyrosine levels 
in patients observed at the NAC, although these reductions were greater in mice, most likely 
owing to patient compliance. A controlled trial in AKU patients would likely see results 
similar to the mouse data shown here. We suggest that strategies reducing tyrosine uptake 
from the intestine, such as degradation of tyrosine by an exogenous enzyme or a tyrosine-
specific binder that prevents uptake into the circulation, that allow a normal protein diet to 
be consumed, could be investigated not only for nitisinone-treated AKU patients, but also 
for nitisinone-treated HT-1 patients.  
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Figure legends 
Figure 1. Tyrosine metabolism pathway. Enzymes are in italics. Disorders are in boxes. NTBC 
(nitisinone) inhibits 4-hydroxyphenylpyruvic acid dioxygenase. 
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 Figure 2. Dietary restriction of tyrosine and phenylalanine in NTBC-treated AKU mice. (A) 
shows when blood samples were taken and when diet conditions were altered. (B) shows 
plasma metabolite levels before NTBC treatment (all mice; n=24), after 1 week of NTBC 
treatment (all mice; n=24), then after 3 (n=6) and 14 days (n=6) of tyrosine/phenylalanine 
restriction. (C) shows the change in bodyweight of individual mice in each group from day 7 
(start of dietary restriction) and day 21 (after 14 days of dietary restriction). 
NTBC=nitisinone. HGA=homogentisic acid. HPPA=4-hydroxyphenylpyruvic acid. HPLA=4-
hydroxyphenyllactic acid. Error bars represent SEM. One-way ANOVA (Tukey post-hoc) 
significance: p<0.05 *, p<0.01 **, p<0.001 ***.  
 
Figure 3. Dietary restriction of phenylalanine in NTBC-treated AKU mice. (A) shows when 
blood samples were taken and when diet conditions were altered. (B) shows the plasma 
metabolite levels before NTBC treatment (all mice; n=24), after 1 week of NTBC treatment 
(all mice; n=24), then after 3 (n=6) and 14 (n=6) days of diet phenylalanine restriction. (C) 
shows the change in bodyweight of individual mice in each group from day 7 (start of 
dietary restriction) and day 14 (after 7 days of dietary restriction). NTBC=nitisinone. 
HGA=homogentisic acid. HPPA=4-hydroxyphenylpyruvic acid. HPLA=4-hydroxyphenyllactic 
acid. Error bars represent SEM. One-way ANOVA (Tukey post-hoc) significance: p<0.05 *, 
p<0.01 **, p<0.001 ***.  
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 Figure 4. Serum tyrosine from 10 AKU patients receiving nitisinone attending the National 
Alkaptonuria Centre. All 10 patients had tyrosine >700µmol/L. Both dietary advice 
(restriction of dietary protein to a recommended minimum level of 0.75g protein/kg 
bodyweight) (n=3) and dietary advice in combination with tyrosine/phenylalanine-free 
amino acid supplements (n=7) reduced serum tyrosine. Initial tyrosine concentrations in the 
group using amino acid supplements were measured after dietary advice alone, with 
subsequent tyrosine concentrations measured after a combination of dietary advice and 
amino acid supplement use. 
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